Romosozumab

Romosozumab, sold under the brand name Evenity, is a medication used to treat osteoporosis. It has been found to decrease the risk of fractures of the spine. Common side effect include headache, joint pain, and pain at the site of injection. It may increase the risk of heart attacks, strokes, and deaths from cardiovascular disease. Romosozumab, sold under the brand name Evenity, is a medication used to treat osteoporosis. It has been found to decrease the risk of fractures of the spine. Common side effect include headache, joint pain, and pain at the site of injection. It may increase the risk of heart attacks, strokes, and deaths from cardiovascular disease. It is a humanized monoclonal antibody that targets sclerostin. Research shows the drug increases bone formation and decreases bone resorption in postmenopausal women with low bone density. Romosozumab was approved for medical use in the United States in 2019. In 2016 results from 12 months of a clinical study were reported. Patients given romosozumab had a lower risk of vertebral fracture than patients given a placebo. Common side effect include headache, joint pain, and pain at the site of injection. It may increase the risk of heart attacks, strokes, and deaths from cardiovascular disease. Romosozumab was approved for medical use in the United States in 2019. It was originally discovered by Chiroscience, which was acquired by Celltech (now owned by UCB). Celltech entered in a partnership with Amgen in 2002 for the product's development.